CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia

被引：2
作者：
Hoelzer, Dieter [1 ]
机构：
[1] Frankfurt Museumsufer, D-60596 Frankfurt, Germany
来源：
CANCER | 2013年 / 119卷 / 15期
关键词：
INOTUZUMAB OZOGAMICIN; PROGNOSTIC-FACTORS; CHEMOIMMUNOTHERAPY; EPRATUZUMAB; RELAPSE; MRD;
D O I：
10.1002/cncr.28135
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Inotuzumab ozogamicin achieves high response and molecular remission rates in patients with relapsed/refractory acute lymphoblastic leukemia with tolerable toxicity. It warrants further studies of inotuzumab in combination with chemotherapy or other targeted therapy.
引用
收藏
页码：2671 / 2674
页数：4
相关论文
共 13 条
  • [1] Advani A, 2012, BLOOD, V120
  • [2] Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
    Advani, Anjali
    Coiffier, Bertrand
    Czuczman, Myron S.
    Dreyling, Martin
    Foran, James
    Gine, Eva
    Gisselbrecht, Christian
    Ketterer, Nicolas
    Nasta, Sunita
    Rohatiner, Ama
    Schmidt-Wolf, Ingo G. H.
    Schuler, Martin
    Sierra, Jorge
    Smith, Mitchell R.
    Verhoef, Gregor
    Winter, Jane N.
    Boni, Joseph
    Vandendries, Erik
    Shapiro, Mark
    Fayad, Luis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2085 - 2093
  • [3] Modern Therapy of Acute Lymphoblastic Leukemia
    Bassan, Renato
    Hoelzer, Dieter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) : 532 - 543
  • [4] Has MRD monitoring superseded other prognostic factors in adult ALL?
    Brueggemann, Monika
    Raff, Thorsten
    Kneba, Michael
    [J]. BLOOD, 2012, 120 (23) : 4470 - 4481
  • [5] Carnahan J, 2003, CLIN CANCER RES, V9, p3982S
  • [6] Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
    Goekbuget, Nicola
    Stanze, Daniel
    Beck, Joachim
    Diedrich, Helmut
    Horst, Heinz-August
    Huettmann, Andreas
    Kobbe, Guido
    Kreuzer, Karl-Anton
    Leimer, Lothar
    Reichle, Albrecht
    Schaich, Markus
    Schwartz, Stefan
    Serve, Hubert
    Starck, Michael
    Stelljes, Matthias
    Stuhlmann, Reingard
    Viardot, Andreas
    Wendelin, Knut
    Freund, Mathias
    Hoelzer, Dieter
    [J]. BLOOD, 2012, 120 (10) : 2032 - 2041
  • [7] Chemoimmunotherapy in acute lymphoblastic leukemia
    Hoelzer, Dieter
    Goekbuget, Nicola
    [J]. BLOOD REVIEWS, 2012, 26 (01) : 25 - 32
  • [8] Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
    Kantarjian, Hagop
    Thomas, Deborah
    Jorgensen, Jeffrey
    Kebriaei, Partow
    Jabbour, Elias
    Rytting, Michael
    York, Sergernne
    Ravandi, Farhad
    Garris, Rebecca
    Kwari, Monica
    Faderl, Stefan
    Cortes, Jorge
    Champlin, Richard
    O'Brien, Susan
    [J]. CANCER, 2013, 119 (15) : 2728 - 2736
  • [9] Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia
    Kantarjian, Hagop
    Thomas, Deborah
    Wayne, Alan S.
    O'Brien, Susan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (31) : 3876 - 3883
  • [10] Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
    Kantarjian, Hagop
    Thomas, Deborah
    Jorgensen, Jeffrey
    Jabbour, Elias
    Kebriaei, Partow
    Rytting, Michael
    York, Sergernne
    Ravandi, Farhad
    Kwari, Monica
    Faderl, Stefan
    Rios, Mary Beth
    Cortes, Jorge
    Fayad, Luis
    Tarnai, Robert
    Wang, Sa A.
    Champlin, Richard
    Advani, Anjali
    O'Brien, Susan
    [J]. LANCET ONCOLOGY, 2012, 13 (04) : 403 - 411
12